PAPULOPUSTULAR FOLLICULAR ERUPTION CAUSED BY CETUXIMAB – TWO CLINICAL CASES.

THE clinical presentation of cutaneous toxicities associated with anticancer therapies is common and polymorphic. The decision to continue the treatment is made with the interdisciplinary cooperation between oncologist and dermatologist, who take into account the severity of these side effects, particularly their impact on the vital prognosis. We present two patients with papulopustular follicular eruption during treatment with cetuximab, which did not require cessation of this drug. Laboratory fi ndings were normal. The histopathological samples from these two cases confi rmed the diagnosis of follicular papulopustular eruption. For the assessment of severity and the effectiveness of treatment we used WoMo Score. After systemic antibiotic therapy with Azithromycin and, Cefi xime respectively, combined with application of an anti-infl ammatory mixture, the evolution was favorable, without Cetuximab discontinuation. Daily sunscreen was prescribed at hospital discharge for both patients. Follicular papulopustular eruption is a common side effect of molecularly targeted therapy with Cetuximab, which often does not require discontinuation of this treatment. [ABSTRACT FROM AUTHOR]